Novartis India Ltd

At Rs 2,195, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Novartis India Ltd locked at its upper circuit of 6.16% on 17 Sep 2026, with buyers queuing and no sellers willing to part with shares.

The Sensex inched up a modest 0.06% on 17 Jun 2026, while Novartis India Ltd surged 7.55%, hitting an intraday high of Rs 2116.6. This 6.21 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific move rather than a broad market lift.

Novartis India Ltd experienced a notable decline today, hitting an intraday low of Rs 1,992.8, reflecting a sharp price pressure of -8.99%. The stock underperformed its sector and broader market indices amid heightened volatility and persistent downward momentum over recent sessions.

Novartis India Ltd experienced a significant intraday decline on 15 Jun 2026, touching a low of Rs 2209.6, down 7.67% from the previous close. The stock underperformed its sector and broader market indices amid widespread selling pressure and a bearish market environment.

Novartis India Ltd (NSE: NOVARTIND) witnessed a remarkable surge in trading activity on 10 Sep 2026, emerging as one of the most actively traded stocks by value in the Pharmaceuticals & Biotechnology sector. The stock soared 11.79% intraday, driven by robust institutional interest and significant order flow, signalling renewed investor confidence in this small-cap pharmaceutical player.

Surging to an all-time high of Rs 2394 on 10 Jun 2026, Novartis India Ltd has demonstrated remarkable price momentum, extending gains for nine consecutive sessions and delivering a 58.26% return during this period. This rally stands out amid a broadly subdued market backdrop, underscoring the stock’s robust technical underpinnings.

Extending its winning streak to nine consecutive sessions, Novartis India Ltd surged to a fresh all-time high of Rs 2,394 on 10 Sep 2026, marking a remarkable 60.54% return over this period and outpacing the Sensex by a wide margin.

The Sensex edged up a marginal 0.05% after a flat start, while Novartis India Ltd surged 7.02% on 10 Jun 2026, hitting a fresh 52-week and all-time high of Rs 2394. This 9.07-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a broad market lift.

At Rs 2,186.40, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Novartis India Ltd locked at its upper circuit of 20% on 9 Sep 2026, with buyers queuing and no sellers willing to part with shares.

Surging past its previous peaks, Novartis India Ltd touched a fresh 52-week high of Rs 2067.5 on 09 Sep 2026, marking a remarkable rally that has seen the stock gain 37.81% over the past eight consecutive trading days.

A 120.37% stock return in one year. A decline of 4.9% in net profit over the same period. The gap between these two figures — roughly 125 percentage points — is driven by the market's willingness to pay a significantly higher multiple for each rupee of Novartis India Ltd's earnings. That divergence is the central story behind this multibagger rally.

Extending its winning streak to eight consecutive sessions, Novartis India Ltd surged 11.00% today to touch a fresh all-time high of Rs 2,000, significantly outpacing the Sensex which declined 0.68% in the same period.

The Sensex declined 0.7% on 09 Jun 2026, while Novartis India Ltd surged 9.41%, touching a fresh 52-week and all-time high of Rs 2000. This 7.35-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally amid a broadly weak market environment.

Novartis India Ltd has seen its investment rating upgraded from Hold to Buy, driven by a marked improvement in technical indicators, robust financial performance in Q1 FY26-27, and sustained long-term growth metrics. The company’s stock has surged over 11% in a single day, reflecting renewed investor confidence amid a backdrop of strong operational fundamentals and market-beating returns.

Novartis India Ltd has demonstrated a significant shift in price momentum, moving from a mildly bullish to a bullish technical trend, supported by robust signals across multiple indicators. The stock’s recent surge of 11.19% in a single day, closing at ₹1,823.35, underscores renewed investor confidence amid a broader pharmaceutical sector recovery.

Surging past its previous peaks, Novartis India Ltd touched a fresh 52-week high of Rs 1850.95 on 8 Sep 2026, marking a remarkable rally that has seen the stock gain nearly 95% over the past year despite a broadly declining market backdrop.

While the Sensex declined by 0.57% on 8 Sep 2026, Novartis India Ltd surged 7.85%, reaching an intraday high of Rs 1750. This 4.25 percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally in a broadly weak market environment.